Cardax clinches deal with HECL for distribution of ZanthoSyn

Cardax asserted that it has forayed into a Purchase Agreement with Health Elite Club limited of Hong Kong for distribution of ZanthoSyn implied for inflammatorry health and longevity in China, Hong Kong, Macau, and Taiwan.

ZanthoSyn will be distributed in the Territories under HECL’s house brand, Puerfons, with all packaging and marketing materials to feature the ZanthoSyn brand. HECL is responsible for all regulatory approvals in the Territories and the Agreement is governed by the laws of New York.

David G. Watumull, Cardax President and CEO said “HECL’s distribution model looks quite promising and their principals are highly credible. We look forward to building our relationship as HECL’s business grows in China.”

The agreement is in line with Cardax’s mission to develop and commercialize the safest, most effective anti-inflammatory products for health and longevity. Cardax is also developing and commercializing CDX-085, its next generation patented ZanthoSyn product for more concentrated astaxanthin product applications.